X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering | X4 Pharmaceuticals, Inc.
Summary
X4 Pharmaceuticals priced a $135 million underwritten public offering of common stock and pre-funded warrants. The company expects to close the offering on October 27, 2025, subject to customary conditions. X4 plans to use the proceeds to fund the pivotal Phase 3 development of mavorixafor and support general corporate needs. The company also granted underwriters a 30-day option to buy additional shares.
Funding
Amount
$135.0M
Total raised
Date
October 24, 2025
Announcement date
Investors
Stifel, Nicolaus & Company, Leerink Swann & Company, Pro Motors Group, Guggenheim Partners
Lead investors
Company
X4pharma.com
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected